07.27.20

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

Source: Oculis

07.10.20

Kodiak Sciences Announces New Longer-Term Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

06.24.20

AsclepiX Therapeutics Announces $35 Million Series A Financing

Source: AsclepiX Therapeutics

05.29.20

Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidate

Source: Adverum Biotechnologies

02.10.20

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

Source: Oculis

02.10.20

Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

02.10.20

Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DME

Source: Oxurion

01.15.20

Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumab

Source: Genentech

01.07.20

Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DME

Source: Oxurion

10.12.19

Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVO

Source: Kodiak Sciences

View more stories